Nishant R. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nishant R. Shah has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Einstein
Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital (A.J.E.).
2 shared publications - David E. Winchester
Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL, United States
2 shared publications - Mrinali Shetty
Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, United States
2 shared publications - Olivier Florian Clerc
Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
2 shared publications - Prem Soman
University of Pittsburgh Medical Center
2 shared publications - Ron Blankstein
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102768
Corrigendum to “The evolution of Tc-99m-labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art” [J Nucl Cardiol 59(S) (2026) 102735]
- 29 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102768
Open AccessCorrigendum to “The evolution of Tc-99m-labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art” [J Nucl Cardiol 59(S) (2026) 102735]
- Open Access
- 15 May 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 59, 102735
The evolution of Tc-99m- labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art
- 15 May 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 59, 102735
Open AccessThe evolution of Tc-99m- labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art
- Open Access
- 22 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e036995
Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis
- 22 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e036995
Open AccessImproving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis
- 22 January 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 31, 101772
Listening is still the first ‘test’ in diagnosing patients with chest pain
- 22 January 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 31, 101772
Listening is still the first ‘test’ in diagnosing patients with chest pain
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (19) , e163
Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study
Kim D, et al. J Korean Med Sci. 2024 May;39(19):e163. https://doi.org/10.3346/jkms.2024.39.e163
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (19) , e163
Open AccessDiagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study
Kim D, et al. J Korean Med Sci. 2024 May;39(19):e163. https://doi.org/10.3346/jkms.2024.39.e163
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 5 (5) , e220288
Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
To characterize the recovery of diagnostic cardiovascular procedure volumes in U.S. and non-U.S. facilities in the year following the initial COVID-19 outbreak. The International Atomic Energy Agency (IAEA) coordinated a worldwide study called the IAEA Noninvasive Cardiology Protocols Study of COVID-19 2 (INCAPS COVID 2), collecting data from 669 facilities in 107 countries, including 93 facilities in 34 U.S. states, to determine the impact of the pandemic on diagnostic cardiovascular procedure volumes. Participants reported volumes for each diagnostic imaging modality used at their facility for March 2019 (baseline), April 2020, and April 2021. This secondary analysis of INCAPS COVID 2 evaluated differences in changes in procedure volume between U.S. and non-U.S. facilities and among U.S. regions. Factors associated with return to prepandemic volumes in the United States were also analyzed in a multivariable regression analysis. Reduction in procedure volumes in April 2020 compared with baseline was similar for U.S. and non-U.S. facilities (−66% vs −71%, P = .27). U.S. facilities reported greater return to baseline in April 2021 than did all non-U.S. facilities (4% vs −6%, P = .008), but there was no evidence of a difference when comparing U.S. facilities with non-U.S. high-income country (NUHIC) facilities (4% vs 0%, P = .18). U.S. regional differences in return to baseline were observed between the Midwest (11%), Northeast (9%), South (1%), and West (−7%, P = .03), but no studied factors were significant predictors of 2021 change from prepandemic baseline. The reductions in cardiac testing during the early pandemic have recovered within a year to prepandemic baselines in the United States and NUHICs, while procedure volumes remain depressed in lower-income countries. Keywords: SPECT, Cardiac, Epidemiology, Angiography, CT Angiography, CT, Echocardiography, SPECT/CT, MR Imaging, Radionuclide Studies, COVID-19, Cardiovascular Imaging, Diagnostic Cardiovascular Procedure, Cardiovascular Disease, Cardiac Testing Supplemental material is available for this article. © RSNA, 2023
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 5 (5) , e220288
Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
To characterize the recovery of diagnostic cardiovascular procedure volumes in U.S. and non-U.S. facilities in the year following the initial COVID-19 outbreak. The International Atomic Energy Agency (IAEA) coordinated a worldwide study called the IAEA Noninvasive Cardiology Protocols Study of COVID-19 2 (INCAPS COVID 2), collecting data from 669 facilities in 107 countries, including 93 facilities in 34 U.S. states, to determine the impact of the pandemic on diagnostic cardiovascular procedure volumes. Participants reported volumes for each diagnostic imaging modality used at their facility for March 2019 (baseline), April 2020, and April 2021. This secondary analysis of INCAPS COVID 2 evaluated differences in changes in procedure volume between U.S. and non-U.S. facilities and among U.S. regions. Factors associated with return to prepandemic volumes in the United States were also analyzed in a multivariable regression analysis. Reduction in procedure volumes in April 2020 compared with baseline was similar for U.S. and non-U.S. facilities (−66% vs −71%, P = .27). U.S. facilities reported greater return to baseline in April 2021 than did all non-U.S. facilities (4% vs −6%, P = .008), but there was no evidence of a difference when comparing U.S. facilities with non-U.S. high-income country (NUHIC) facilities (4% vs 0%, P = .18). U.S. regional differences in return to baseline were observed between the Midwest (11%), Northeast (9%), South (1%), and West (−7%, P = .03), but no studied factors were significant predictors of 2021 change from prepandemic baseline. The reductions in cardiac testing during the early pandemic have recovered within a year to prepandemic baselines in the United States and NUHICs, while procedure volumes remain depressed in lower-income countries. Keywords: SPECT, Cardiac, Epidemiology, Angiography, CT Angiography, CT, Echocardiography, SPECT/CT, MR Imaging, Radionuclide Studies, COVID-19, Cardiovascular Imaging, Diagnostic Cardiovascular Procedure, Cardiovascular Disease, Cardiac Testing Supplemental material is available for this article. © RSNA, 2023
- 22 August 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (9) , 1235-+
The Medicare Appropriate Use Criteria Program: A Review of Recommendations for Testing in Coronary Artery Disease
Background: Congress established the Appropriate Use Criteria (AUC) Program to reduce unnecessary advanced imaging studies. Organizations that wish to develop AUC can apply to the Centers for Medicare & Medicaid Services (CMS) to qualify as provider-led entities (PLEs) under this program. Variable methods, content, and formatting of PLE-generated AUC could lead to clinician uncertainty about whether an advanced imaging test is appropriate or not.Purpose: To review AUC published by CMS-qualified PLEs focused on advanced imaging tests for coronary artery disease (CAD), a "priority clinical area" identified by CMS.Data Sources: Publicly available data from the worldwide web searched on 29 August 2022.Study Selection: Approved AUC with recommendations related to testing for CAD.Data Extraction: Manual review of published AUC by all authors.Data Synthesis: Among the 17 CMS-qualified PLEs, only 7 had published AUC related to CAD. Substantial variation in the methods and formatting of these AUCs was observed. The number of clinical scenarios covered ranged from 6 to 210, and the number of advanced imaging methods covered ranged from 1 to 25. When specifically applied to clinical scenarios, many AUC offered no guidance on appropriateness; those that did conflicted with respect to appropriateness.Limitation: Other CMS-identified priority clinical areas were not evaluated.Conclusion: CMS-qualified AUC for imaging of CAD are heterogeneous and sometimes discrepant, creating substantial potential for uncertainty among clinicians seeking to provide their patients with appropriate imaging tests.
- 22 August 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (9) , 1235-+
The Medicare Appropriate Use Criteria Program: A Review of Recommendations for Testing in Coronary Artery Disease
Background: Congress established the Appropriate Use Criteria (AUC) Program to reduce unnecessary advanced imaging studies. Organizations that wish to develop AUC can apply to the Centers for Medicare & Medicaid Services (CMS) to qualify as provider-led entities (PLEs) under this program. Variable methods, content, and formatting of PLE-generated AUC could lead to clinician uncertainty about whether an advanced imaging test is appropriate or not.Purpose: To review AUC published by CMS-qualified PLEs focused on advanced imaging tests for coronary artery disease (CAD), a "priority clinical area" identified by CMS.Data Sources: Publicly available data from the worldwide web searched on 29 August 2022.Study Selection: Approved AUC with recommendations related to testing for CAD.Data Extraction: Manual review of published AUC by all authors.Data Synthesis: Among the 17 CMS-qualified PLEs, only 7 had published AUC related to CAD. Substantial variation in the methods and formatting of these AUCs was observed. The number of clinical scenarios covered ranged from 6 to 210, and the number of advanced imaging methods covered ranged from 1 to 25. When specifically applied to clinical scenarios, many AUC offered no guidance on appropriateness; those that did conflicted with respect to appropriateness.Limitation: Other CMS-identified priority clinical areas were not evaluated.Conclusion: CMS-qualified AUC for imaging of CAD are heterogeneous and sometimes discrepant, creating substantial potential for uncertainty among clinicians seeking to provide their patients with appropriate imaging tests.
- Open Access
- 24 August 2022
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 23 (9) , 293
Appropriateness of Cardiovascular Imaging in the Initial Assessment of Possible Acute Coronary Syndrome in the Emergency Department
Patients presenting with chest pain and related symptoms account for over 6 million emergency department (ED) visits in the United States annually. However, less than 5% of these patients are ultimately diagnosed with acute coronary syndrome (ACS). ED clinicians face the diagnostic challenge of promptly identifying and treating these high-risk patients amidst the overwhelming majority of lower-risk patients for whom further testing and/or treatment is either unnecessary or non-urgent. To assist with and expedite risk stratification and decision-making in this challenging clinical scenario, diagnostic tools like clinical risk scores and high-sensitivity serum biomarkers have been incorporated into care algorithms within the ED. In this narrative review, we discuss how these tools impact the appropriate use of cardiovascular imaging in the initial assessment of patients presenting to the ED with possible ACS.
- 24 August 2022
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 23 (9) , 293
Open AccessAppropriateness of Cardiovascular Imaging in the Initial Assessment of Possible Acute Coronary Syndrome in the Emergency Department
Patients presenting with chest pain and related symptoms account for over 6 million emergency department (ED) visits in the United States annually. However, less than 5% of these patients are ultimately diagnosed with acute coronary syndrome (ACS). ED clinicians face the diagnostic challenge of promptly identifying and treating these high-risk patients amidst the overwhelming majority of lower-risk patients for whom further testing and/or treatment is either unnecessary or non-urgent. To assist with and expedite risk stratification and decision-making in this challenging clinical scenario, diagnostic tools like clinical risk scores and high-sensitivity serum biomarkers have been incorporated into care algorithms within the ED. In this narrative review, we discuss how these tools impact the appropriate use of cardiovascular imaging in the initial assessment of patients presenting to the ED with possible ACS.
- 1 June 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 4 (3) , e220008
Cardiac MRI Findings in Male Patients with Acute Myocarditis in the Presence or Absence of COVID-19 Vaccination
By comparing phenotypic clinical characteristics and cardiovascular magnetic resonance (CMR) findings in 14 patients with COVID-19 mRNA vaccine-associated myocarditis to 14 patients with acute myoc...
- 1 June 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 4 (3) , e220008
Cardiac MRI Findings in Male Patients with Acute Myocarditis in the Presence or Absence of COVID-19 Vaccination
By comparing phenotypic clinical characteristics and cardiovascular magnetic resonance (CMR) findings in 14 patients with COVID-19 mRNA vaccine-associated myocarditis to 14 patients with acute myoc...